Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status.
Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Antonio Giordano(University of Siena), Agnese Montanino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mario Giuliano(Regione Campania), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Brigida Stanzione(National Cancer Institute), Carmen Criscitiello(University of Milan), R. Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudette Falato(Karolinska Institutet)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Curcumin and Cancer
|Nutrients|2019|977
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Role of p53 in the Regulation of Cellular Senescence
|Biomolecules|2020|605